Institutional Perspectives in Cancer- Breast Cancer: Chaired by Angela DeMichele, MD, MSCE

Video

Institutional Perspectives in Cancer- Breast Cancer: Chaired by Angela DeMichele, MD, MSCE

The live filming of this virtual event in our IPC series is now on-demand.

OncLive is proud to present the State of the Science Summits and a new virtual event, Institutional Perspectives in Cancer (IPC). Each summit and webinar will convene for a short meeting designed to educate healthcare professionals on the clinical benefits associated with new science driving new thinking in cancer management. Attendees will not only improve their knowledge of novel treatment approaches, but also leave the event the with confidence and intent to apply state-of-the-art treatment strategies to care for their patients. Each event is dedicated to the latest research in one of the following therapeutic areas: Breast Cancer, Lung Cancer, GU & Prostate Cancer, Hematology, or Melanoma.

The State of the Science Summits and IPC assemble academic and community-based physicians & healthcare professionals across key disciplines from medical and surgical oncology. Specialist experts serve as faculty for these premier and renowned oncology summits, which focus on the most relevant cancer topics to ultimately improve patient care.

Speakers:

  • Rachel C. Jankowitz, MD | Penn Medicine
  • Amy S. Clark, MD, MSCE | Penn Medicine
  • Angela DeMichele, MD, MSCE| Penn Medicine
  • Lola Fayanju, MD, MA, MPHS, FACS | Penn Medicine

Topics:

  • Updates in HER2+ Breast Cancer
  • Updates in Adjuvant and Metastatic HR+/HER2- Breast Cancer
  • Updates in Triple-Negative Breast Cancer
  • Updates in Locoregional Management of Breast Cancer

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
Nan Chen, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Carlos Arteaga, MD
Video 2 - "NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer"
Reshma L. Mahtani, DO